Published in Onco Targets Ther on June 13, 2017
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol (2005) 2.43
Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene (2011) 1.44
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer (2004) 1.09
Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol (2011) 1.09
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells (2014) 1.01
Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer (2000) 0.99
Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.96
Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. Biochim Biophys Acta (2016) 0.96
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 0.95
Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One (2013) 0.93
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol (2005) 0.92
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. J Cancer (2014) 0.90
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int (2016) 0.87
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PLoS One (2014) 0.87
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget (2016) 0.86
CD133, Selectively Targeting the Root of Cancer. Toxins (Basel) (2016) 0.83
The identification of the biological characteristics of human ovarian cancer stem cells. Eur Rev Med Pharmacol Sci (2014) 0.83
Prognostic value of CD117 in cancer: a meta-analysis. Int J Clin Exp Pathol (2014) 0.83
Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev (2013) 0.82
Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Curr Protein Pept Sci (2015) 0.81
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget (2015) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer (2017) 0.80
Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther (2015) 0.78
Ovarian stem cells: From basic to clinical applications. World J Stem Cells (2015) 0.77
Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma. Biomed Res Int (2015) 0.77
Tryptase-positive and CD117 Positive Mast Cells Correlate with Survival in Patients with Liver Metastasis. Anticancer Res (2015) 0.76
The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol (2005) 0.76
Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases. Coll Antropol (2015) 0.76
The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis. Cancer Cell Int (2017) 0.75
Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy. J Obstet Gynaecol Res (2015) 0.75
Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res (2017) 0.75